There are currently 48 ongoing clinical trials involving Fistula
Of the 48 trials,19 trials are in Phase III
Furthermore, 18 trials are in Phase II
The global pharmaceutical industry is steadily developing new drugs for Fistula, other diseases. The largest number of ongoing clinical trials for Fistula is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Fistula-related drug trials.
The Cleveland Clinic Foundation: The leading ongoing Fistula related clinical trial sponsor
The Cleveland Clinic Foundation is the top sponsor for Fistula-related ongoing clinical trials.
Mayo Clinic, Tongji Medical College, Assiut University, Okayama University Hospital, and Anterogen Co Ltd are among other notable clinical trial sponsors involved in Fistula. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Fistula
Bacitracin and Neomycin sulfate (Neobacitracine), Heparin sodium, lidocaine hydrochloride and prednisolone (Gepazolon), and Lidocaine and Sucralfate (Sucralcoat Ano) are key marketed drugs involving Fistula.
Bacitracin and Neomycin sulfate (Neobacitracine) is a fixed-dose combination that acts as an anti-bacterial agent. It functions via 30S Ribosomal Subunit (30S RNA) Inhibitor; C55 Isoprenyl Pyrophosphate Inhibitor mechanism of action. It is formulated as powder and solvent for suspension for an ophthalmic, otic, and nasal route of administration and cutaneous application. Neobacitracine is indicated for local antibiotic treatment of infections caused by susceptible germs such as conjunctivitis, keratitis, styes, dacryocystitis, infectious rhinitis, infections of the external auditory canal, prophylaxis and treatment of infection of wounds and burns. Bacitracin and Neomycin sulfate was first approved in 1961 and is marketed in Belgium by BePharBel SA.
Heparin sodium, lidocaine hydrochloride, and prednisolone (Gepazolon) is fixed-dose combination drug. It functions via Antithrombin III (ATIII or SERPINC1) Activator; Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonist; Voltage-Gated Sodium Channel (SCN) Blocker mechanism of action. It is formulated as suppositories for rectal administration. It is indicated for thrombophlebitis, atopic dermatitis (eczema), anal fissure, hemorrhoids, and fistula. It is also used in surgical intervention in the anorectal area and thrombosed hemorrhoids. Heparin sodium, lidocaine hydrochloride, and prednisolone was first approved in 2009 and is marketed in Russia by Altfarm Ltd.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward